Derms Seek Minimally Invasive Rx Mostly From Other Derms

This article originally appeared here.
Share this content:
Derms Seek Minimally Invasive Rx Mostly From Other Derms
Derms Seek Minimally Invasive Rx Mostly From Other Derms

MONDAY, June 27, 2016 (HealthDay News) -- A majority of female dermatologists undergo minimally invasive cosmetic procedures (MICPs), and most choose other dermatologists to perform the procedures, according to a study published online June 20 in the Journal of Cosmetic Dermatology.

Hamza Yildiz, M.D., from the Eskisehir Military Hospital in Turkey, and colleagues conducted a cross-sectional descriptive study among 318 dermatologists (73.3 percent female). The participants completed an 11-item questionnaire to examine use of MICP.

The researchers found that 56 percent of the dermatologists underwent MICPs (66.1 percent among females and 28.2 percent among males; P < 0.001). They mainly selected dermatologists to perform the procedures (91 percent), which were primarily carried out in private settings (67.2 percent). Most MICPs were performed after medical residency (75.3 percent). The most important criterion was physicians' experience (66.9 percent). More than three-quarters (76.4 percent) of those who did not have MICPs were intending to have them. "Not need yet" was reported as the most frequent reason for not having MICPs (62.1 percent).

"The data in this survey demonstrated that dermatologist was the most preferred physician by dermatologists who had MICPs," the authors write. "The reason for this high rate may be due to immediate and easy accessibility to the dermatologists for the procedures and trust [in] the dermatologists. Experience was the most important reason for choosing a physician."

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

FDA Approves First Drug for Rare Form of Rickets

FDA Approves First Drug for Rare Form of ...

Crysvita approved for adults and children ages 1 year and older with x-linked hypophosphatemia

High FGF-23 Linked to Recurrent Cardiac Events After ACS

High FGF-23 Linked to Recurrent Cardiac Events After ...

FGF-23 in top quartile independently linked to greater risk of CV death, heart failure hospitalization

Medical Cannabis Not Recommended for Sleep Apnea

Medical Cannabis Not Recommended for Sleep Apnea

American Academy of Sleep Medicine says evidence insufficient to recommend cannabis for apnea

is free, fast, and customized just for you!

Already a member?

Sign In Now »